Dark Blue Therapeutics is an innovative drug discovery biotechnology company leveraging ground-breaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology, Dark Blue Therapeutics matches its precision medicines to molecularly defined patient populations to develop transformative, durable …

Qubit Pharmaceuticals aims to speed up the lengthy and costly drug discovery process, where potential drugs are screened from a very large number of molecules. It increases the accuracy of these calculations by leveraging the power of its own 200 GPU supercomputer, called Gaia, developed in partnership with Nvidia. Qubit’s software, called Atlas, has been …

Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. The company is building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each …

With its AI-driven drug discovery platform, Tailor Bio is bringing precision medicine to the deadliest cancers. It provides clinical decision support to physicians, allowing them to select the best therapy for their patients’ treatments. To do this, Tailor Bio’s technology decodes chromosomal instability — a genomic phenomenon present in 80% of all cancers — and …

Kuano combines quantum physics, AI and medicinal chemistry in an approach to transforming the discovery of therapeutics focused on enzyme inhibition. Enzymes represent the largest class of drug targets, with over $40 billion of pharmaceutical sales attributable to small molecule inhibitors of enzymes. The market is seeing considerable demand for enzyme inhibitors, which can provide …

Founded through a collaboration between argenx and the University of Torino, Italy – Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is …

ELEM Biotech is developing a Virtual Human technology that it hopes to become the standard for medical testing and in-silico clinical trials. More specifically, the company is creating cutting-edge supercomputer-based patient modeling and simulation solutions, deployed in the cloud, that help MedTech and Pharma companies, and CROs optimize their products and offer new evidence to …

CancerAppy has developed a platform based on Big Data and AI, specialized in the field of cancer research, developed by and for scientists and drug developers that fills the gap between basic data tools and pharma intelligence tools. Said platform is meant to efficiently and effectively de-risk the process of cancer drug discovery and development …